Hamster study found that a COVID vaccine designed to be taken as a pill results in neutralization of the SARS-CoV-2 virus in mucosal tissues
Duke researchers have shown that SARS-CoV-2 can infect kidney cells via multiple binding sites and use the cell’s machinery to replicate, causing injury and kidney disease. The discovery helps explain why acute kidney injury is one of the main complications observed in patients with severe COVID.
Duke in DC and Duke Health Government Relations convened a group of Duke experts to brief federal policymakers on the importance of federal investment in research, the impacts from their work, and additional recommendations to bolster our nation’s public health, medical preparedness, and response systems
Researchers at the Duke Human Vaccine Institute have demonstrated a successful way to deliver a potential HIV vaccine using mRNA technology, like that in the COVID-19 vaccines.
According to a study by the ABC Science Collaborative, school districts that required masking saw lower rates of COVID-19 transmission within schools last fall compared to those with optional masking policies.
Two Duke pulmonologists speak with the media about symptoms, treatments and what remains unknown about long COVID.
Unvaccinated students had eight times the incidence of COVID-19 infection compared to vaccinated students in a North Carolina independent school, according to a study by the ABC Science Collaborative appearing online Feb. 22 in the journal Pediatrics.
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University has expanded its testing platform to evaluate ivermectin at a higher dose for a longer period of time.
A booster dose of Moderna’s COVID-19 vaccine showed signs of waning antibody levels against the Omicron variant after six months, but the antibodies still remained effective against the variant in laboratory tests, according to a Jan. 26 study in the New England Journal of Medicine.
A new infusion being offered by Duke HomeCare & Hospice. Certain patients who test positive for COVID-19 are eligible for an infusion designed to decrease the risk of transmission, stimulate a stronger immune response, decrease symptoms and make it less likely a recovery in the hospital will be necessary.